Gilead and ViiV Healthcare Settle Global Patent Dispute for Over $1B USD
IPilogue
APRIL 22, 2022
This article delves into the legal doctrines that support the parties’ claims and the overarching strategy to their settlement. ViiV alleges Gilead infringed upon patent 385 under the doctrine of equivalents, which has two exclusions: dedication-disclosure and specific exclusion. sales of Biktarvy. Concluding Remarks.
Let's personalize your content